Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
In this study, we investigated the relationships of pathological response after neoadjuvant chemo-endocrine therapy with alterations in the Ki67 labeling index (LI), expression of cyclin D1 (CCND1) and progesterone receptor (PgR), and estrogen receptor (ER) activity in breast cancer. A total of 43 J...
Main Authors: | Sasagu Kurozumi, Yuri Yamaguchi, Hiroshi Matsumoto, Masafumi Kurosumi, Shin-Ichi Hayashi, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Kenichi Inoue |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0217279 |
Similar Items
-
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
by: Sasagu Kurozumi, et al.
Published: (2018-01-01) -
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
by: Sasagu Kurozumi, et al.
Published: (2017-05-01) -
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
by: Luca Gianni, et al.
Published: (2022-01-01) -
The Er/Ki-67 Proportion in Breast Tumours - An Immunohistochemical Study
by: Rachna, et al.
Published: (2016-04-01) -
The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
by: Ailin Zhang, et al.
Published: (2021-11-01)